ViE Awards 2016 – Voting is now open!

After weeks of voting and over 1000 nominations collected, we are happy to announce the highly nominated companies in each category as voted by you and your peers for the 9th annual Vaccine Industry Excellence (ViE) Awards in the following categories Best Clinical Trial Site AND Network Best Contract Research Organization Best Contract Manufacturing Organization Best Production/Process Development  Best Academic Research Team …

CFDA approves production of the first Sabin IPV

China Food and Drug Administration (CFDA) has approved the production of the first inactivated poliomyelitis vaccine made from inactivated Sabin strains (Sabin IPV). It was researched and developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences. Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the poliovirus. It is a virus-transmitted disease that …

Retroscreen Virology Senior Medical Director to speak at World Vaccine Congress USA 2015

The world’s leading research company in human viral challenge models, Retroscreen Virology, has announced one of its scientific and medical leadership team will be speaking at 2015 World Vaccine Congress in the USA. Dr Martin Johnson, Senior Medical Director at Retroscreen Virology, is going to be talking about the Retroscreen hVIVO human viral challenge model and how it can be …

Cancer vaccine trial in Singapore shows promising signs of success

A cancer vaccine suitable for lung, breast, prostate, colon and ovarian cancer has shown promising results in a vaccine trial conducted in Singapore. It was tested for the first time on four patients with Stage 4 cancer and no major side effects have been observed yet. The vaccine trial was launched by the National Cancer Centre of Singapore in September …

PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

Positive Lot-to-Lot Consistency Data Pave Way for Biologics License Application (BLA) Submission in 2015 December 8, 2014 PaxVax Inc., a specialty vaccine company focused on travel and biodefense, today announced positive results from a Phase 3 safety and lot-to-lot consistency trial of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved …

CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites

Sites in Europe and Asia add to patient enrollment and position Company to apply for global regulatory approvals December 8, 2014 CEL-SCI Corporation today announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). Patient screening has begun at new clinical …

SAB Biotherapeutics and U.S. Army team up to treat Hantavirus

Human antibodies produced in genetically designed cows can protect against deadly diseases December 3, 2014 SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, has teamed up with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to address the potentially deadly hantavirus using a novel approach to developing protective antibodies against it. Their work, published in the November …

CDC: Early Data Suggests Potentially Severe Flu Season

December 5, 2014 Early data suggests that the current 2014-2015 flu season could be severe. The Centers for Disease Control and Prevention (CDC) urges immediate vaccination for anyone still unvaccinated this season and recommends prompt treatment with antiviral drugs for people at high risk of complications who develop flu. So far this year, seasonal influenza A H3N2 viruses have been …